Literature DB >> 8233496

Audiologic monitoring for ototoxicity.

K C Campbell1, J Durrant.   

Abstract

In summary, the clinician has a variety of protocols available for monitoring ototoxicity. Depending on the patient's risk factors and ability to be tested, the protocol for a given patient may vary. A flow chart reflecting some of the possible decisions and options is presented in Figure 1. Certainly, as we learn more about ototoxicity and the advantages and disadvantages of the various test methods, further refinements of patient and test selection will ensue. Ototoxicity is a rapidly expanding and interesting area. Hopefully, the care of patients receiving ototoxic medications will continue to improve and will ultimately prevent, or at least ameliorate, ototoxic hearing loss.

Entities:  

Mesh:

Year:  1993        PMID: 8233496

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  11 in total

1.  Is vancomycin ototoxicity a significant risk?

Authors:  Ryan K Shields; Jay L Martello; Brian A Potoski
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

2.  Distortion-product otoacoustic emission test performance for ototoxicity monitoring.

Authors:  Kelly M Reavis; Garnett McMillan; Donald Austin; Frederick Gallun; Stephen A Fausti; Jane S Gordon; Wendy J Helt; Dawn Konrad-Martin
Journal:  Ear Hear       Date:  2011-02       Impact factor: 3.570

Review 3.  Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group.

Authors:  Johnnie K Bass; Kristin R Knight; Torunn I Yock; Kay W Chang; Douglas Cipkala; Satkiran S Grewal
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

4.  Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.

Authors:  Johnnie K Bass; Jie Huang; Arzu Onar-Thomas; Kay W Chang; Shaum P Bhagat; Murali Chintagumpala; Ute Bartels; Sridharan Gururangan; Tim Hassall; John A Heath; Geoffrey McCowage; Richard J Cohn; Michael J Fisher; Giles Robinson; Alberto Broniscer; Amar Gajjar; James G Gurney
Journal:  Pediatr Blood Cancer       Date:  2013-11-01       Impact factor: 3.167

5.  Hearing and cochlear function of patients with ankylosing spondylitis.

Authors:  Orhan Kemal Kahveci; Umit Secil Demirdal; Abidin Duran; Ali Altuntas; Vural Kavuncu; Erdogan Okur
Journal:  Clin Rheumatol       Date:  2012-04-17       Impact factor: 2.980

6.  Role of Otoacoustic Emission in Early Detection of Cisplatin Induced Ototoxicity.

Authors:  Shama Shetty; Satheesh Kumar Bhandary; Vadisha Bhat; Rajeshwary Aroor; Jayarama Shetty; T Dattatreya
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-07-01

7.  Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.

Authors:  Christine E McLaren; Sharon Fujikawa-Brooks; Wen-Pin Chen; Daniel L Gillen; Daniel Pelot; Eugene W Gerner; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2008-12

8.  Highly active antiretroviral therapy: Does it Sound toxic?

Authors:  Katijah Khoza-Shangase
Journal:  J Pharm Bioallied Sci       Date:  2011-01

9.  Long-term vancomycin use had low risk of ototoxicity.

Authors:  Clayton Humphrey; Michael P Veve; Brian Walker; Mahmoud A Shorman
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

10.  Possible Ototoxic Effects of Topical Rifamycin Application: An Electrophysiological and Ultrastructural Study.

Authors:  Cihan Abaylı; Yusuf Kul; Muhsin Koten; Ahmet Rıfat Karasalihoğlu; Abdullah Taş; Recep Yağız; Erdoğan Bulut
Journal:  Turk Arch Otorhinolaryngol       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.